Skip to main content
European Medicines Agency's logo Go to homepage

Main navigation

  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. Adcetris - withdrawal of application for variation to marketing authorisation

Adcetris - withdrawal of application for variation to marketing authorisation

Application withdrawn

The application for a change to this medicine's authorisation has been withdrawn.

brentuximab vedotin
Post-authorisationHuman

Page contents

  • Overview
  • Key facts
  • Documents
  • Related information on withdrawals
  • News on Adcetris
  • More information on Adcetris

Overview

Takeda Pharma A/S withdrew its application for the use of Adcetris in adults with previously untreated CD30-positive peripheral T-cell lymphoma not otherwise specified (PTCL-NOS).

The company withdrew the application on 23 February 2024.

Adcetris is a cancer medicine used to treat adults with certain lymphomas (cancers of lymphocytes, types of white blood cells) when the cancer cells have a protein called CD30 on their surface (CD30‑positive).

In Hodgkin’s lymphoma, Adcetris is used:

  • together with doxorubicin, vinblastine and dacarbazine (other cancer medicines) in patients whose cancer is advanced (stage III or IV disease) and has not been treated before;
  • when the cancer has come back or has not responded to an autologous stem cell transplant (a transplant of the patient's own blood-producing cells);
  • if the cancer is likely to come back or get worse after an autologous stem cell transplant;
  • when the cancer has come back or has not responded to at least two other therapies and when autologous stem cell transplant or multi-agent chemotherapy (a combination of cancer medicines) cannot be used.

In non-Hodgkin’s lymphoma, Adcetris is used for:

  • systemic anaplastic large cell lymphoma (sALCL, a cancer of lymphocytes called T cells) when the cancer has never been treated before; Adcetris is used together with cyclophosphamide, doxorubicin and prednisone. It is also used when the cancer has come back or when other treatments have not worked;
  • cutaneous T-cell lymphoma (CTCL), a lymphoma of T cells that initially affects the skin, in patients who have received at least one previous treatment.

Adcetris has been authorised in the EU since October 2012. It contains the active substance brentuximab vedotin and is available as a powder that is made into a solution for infusion (drip) given into a vein.

The company applied to extend the use of Adcetris to adults with CD30-positive peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), when the cancer has not been treated before. Adcetris was intended to be used in combination with cyclophosphamide, doxorubicin and prednisone.

Adcetris was designated an ‘orphan medicine’ (a medicine used in rare diseases) for peripheral T cell lymphoma 21 August 2019.

The active substance in Adcetris, brentuximab vedotin, is made up of a monoclonal antibody (a type of protein) that attaches to CD30 and is linked to monomethyl auristatin E, a cytotoxic (cell-killing) molecule. The monoclonal antibody delivers monomethyl auristatin E to the CD30-positive cancer cells. The cytotoxic molecule then enters the cancer cells and prevents them from dividing, causing the cancer cells to die.

The company submitted additional data from a main study involving 452 patients with CD30-positive PTCL who received either Adcetris with cyclophosphamide, doxorubicin and prednisone (Adcetris plus CHP) or a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), a standard treatment. The study looked at how long patients with different subtypes of PTCL lived without their disease getting worse.

The application was withdrawn after the European Medicines Agency had evaluated the initial information from the company and had prepared questions for the company.

Based on the review of the information, at the time of the withdrawal, the Agency’s opinion was that the company had not provided enough information to support the application for a change to the marketing authorisation of Adcetris to include treatment of CD30-positive PTCL-NOS.

The main study involved patients with different types of CD30-positive PTCL; there were too few patients with PTCL-NOS. These patients were not evenly distributed between the two treatment groups and the characteristics of the patients in both groups were not similar. It was also unclear whether results seen in other types of PTCL could be applied to those with PTCL-NOS. Therefore, the Agency considered that there were uncertainties regarding the effectiveness of Adcetris in patients with PTCL NOS.

In its letter notifying the Agency of the withdrawal of application, the company stated that it withdrew its application because the Agency considered that the data provided were not sufficient to support the extension of indication for Adcetris to include adults with previously untreated CD30-positive PTCL-NOS.

There are no consequences for patients in clinical trials using Adcetris.

If you are in a clinical trial and need more information about your treatment, speak with your clinical trial doctor.

There are no consequences on the use of Adcetris in its authorised uses.

Questions and answers on the withdrawal of application to change the marketing authorisation for Adcetris (brentuximab vedotin)

Reference Number: EMA/116069/2024

English (EN) (209.95 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View
Other languages (22)

български (BG) (151.71 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

español (ES) (125 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

čeština (CS) (147.73 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

dansk (DA) (125.4 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

Deutsch (DE) (128.88 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

eesti keel (ET) (123.24 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

ελληνικά (EL) (152.61 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

français (FR) (125.91 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

hrvatski (HR) (146.87 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

italiano (IT) (123.57 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

latviešu valoda (LV) (166.35 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

lietuvių kalba (LT) (149.64 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

magyar (HU) (149.78 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

Malti (MT) (159.12 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

Nederlands (NL) (125.1 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

polski (PL) (158 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

português (PT) (125.25 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

română (RO) (146.05 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

slovenčina (SK) (147.98 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

slovenščina (SL) (147.22 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

Suomi (FI) (123.21 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

svenska (SV) (124.8 KB - PDF)

First published: 22/03/2024Last updated: 18/07/2024
View

Key facts

Name of medicine
Adcetris
EMA product number
EMEA/H/C/002455
Active substance
Brentuximab vedotin
International non-proprietary name (INN) or common name
brentuximab vedotin
Therapeutic area (MeSH)
  • Lymphoma, Non-Hodgkin
  • Hodgkin Disease
Anatomical therapeutical chemical (ATC) code
L01XC12
Marketing authorisation holder
Takeda Pharma A/S
Date of issue of marketing authorisation valid throughout the European Union
25/10/2012
Date of withdrawal
23/02/2024

Documents

Withdrawal letter: Adcetris (II-109)

English (EN) (387 KB - PDF)

First published: 22/03/2024
View

Withdrawal assessment report: Adcetris (II-109)

AdoptedReference Number: EMA/336551/2024

English (EN) (3.46 MB - PDF)

First published: 18/07/2024
View

Related information on withdrawals

The question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 90').

News on Adcetris

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2025
25/04/2025
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024
22/03/2024
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023
15/09/2023
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated)
27/03/2020
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018
14/12/2018
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2017
10/11/2017
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 May 2016
27/05/2016

More information on Adcetris

  • Adcetris
This page was last updated on 18/07/2024

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
Languages
Frequently asked questions
Glossaries
About this website
Cookies
Website data protection notice
Data protection at EMA
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • Bluesky
  • YouTube
  • LinkedIn
© 1995 - 2025 European Medicines Agency
European Union agencies network
An agency of the European Union